CTSO

Cytosorbents Corp (CTS) Q1 2025 Filing Summary

Business Context and Reporting Period

Cytosorbents Corporation (the "Company") is a medical device company focused on blood purification technologies, primarily through its CytoSorb device. The Company operates as a single reportable segment. This summary covers the quarterly period ended March 31, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company. As of May 13, 2025, there were 62,610,376 shares of common stock outstanding.

Key Financial Metrics

Note: The Net Loss for Q1 2025 was significantly reduced by a $3.01 million gain on foreign currency transactions.

Material Changes vs. Prior Period

• Revenue: Decreased 3% year-over-year to $8.73 million. The decline was driven by a temporary disruption in direct sales in Germany due to a strategic realignment of the commercial team, partially offset by growth in distributor territories across the EU.
• Gross Margin: Declined to 71.1% from 76.5%. This was primarily due to a 23% reduction in production volume, which was only partially offset by an 11% reduction in production costs.
• Operating Expenses: Decreased 12% to $10.09 million. Reductions were seen in R&D (down 26% due to the completion of the STAR-T clinical trial) and SG&A (down 9% due to lower royalty expenses and stock-based compensation).
• Foreign Currency: A significant swing occurred from a $1.43 million loss in Q1 2024 to a $3.01 million gain in Q1 2025, driven by the strengthening of the Euro against the U.S. dollar.
• Liquidity: Cash balances increased significantly following a Rights Offering in January 2025 (raising $5.4 million net) and the exercise of Series A warrants in February 2025 (raising $1.4 million net). Additionally, $5 million of restricted cash was released from debt covenants.

Guidance, Outlook, and Risks

• Regulatory Status (DrugSorb-ATR): On April 25, 2025, the FDA issued a denial letter regarding the Company's De Novo Request for DrugSorb-ATR. The Company intends to file a formal appeal by June 25, 2025, and anticipates a final regulatory decision in 2025. Health Canada application remains under advanced review.
• Debt Covenants: The Company has a $20 million credit facility with Avenue Capital Group. Tranche 1 ($15 million) is funded. Tranche 2 ($5 million) is contingent on FDA marketing approval of DrugSorb-ATR by December 31, 2025. Meeting this milestone would extend the principal repayment terms.
• Going Concern: The Company states that its cash position raises substantial doubt about its ability to continue as a going concern without additional financing. Future capital requirements depend on regulatory approvals and commercialization efforts.
• Subsequent Events: In April 2025, the Company received $1.7 million from the sale of Net Operating Loss (NOL) and R&D tax credits via the New Jersey Technology Business Tax Certificate Transfer Program.
• Internal Controls: The Company identified a material weakness in internal controls over financial reporting related to the accounting for non-cash stock-based compensation (RSUs). Remediation efforts are underway.

Investor Verification Checklist

• FDA Appeal Timeline: Verify the status of the formal appeal for DrugSorb-ATR and the likelihood of a 2025 decision, as this is critical for Tranche 2 debt funding and U.S. commercialization.
• Cash Burn Rate: Assess the runway provided by the current $13.1 million cash balance against the reported operating cash burn and upcoming capital needs for the appeal process and commercialization.
• Germany Sales Recovery: Monitor subsequent quarters for the effectiveness of the German commercial team realignment and the return to revenue growth in that key market.
• Debt Maturity: Confirm the interest-only period end date (July 2026) and the conditions required to extend it to January 2027 via Tranche 2 funding.
• Internal Control Remediation: Review future filings for confirmation that the material weakness regarding RSU accounting has been fully remediated.